top of page

Latest News

We help inventions grow!

Feb 7, 2022

New startup in our portfolio: Sophomer's technology will make immunoassays faster, easier and cheaper

The academic startup Sophomer today announced the signing of a licensing agreement to commercialize a technology that can replace the traditionally used bovine serum albumin (BSA) in immunoassays. The newly licensed technology has been developed in collaboration between the Institute of Macromolecular Chemistry of the CAS (IMC), Elisa Development and the bio-innovation center i&i Prague. The signing of the license agreement also officially accelerated the activities of the startup...


Feb 6, 2022

Czech liquid biopsy startup Elphogene comes under full control of one of the founders

Czech biotechnology start-up Elphogene who pioneered cancer monitoring through its liquid biopsy technology has announced a change in its shareholder structure. The new and sole owner is now Marek Minarik, one of the two original founders of the company. In the portfolio of the bio-innovation centre i&i Prague, Elphogene was one of the oldest startups. Now our mission is over.

elphogene - obdelnik.png

Dec 23, 2022

We are looking for new Antonin Holy and new drugs and diagnostics that can have a global impact and success

"i&i Bio invests in technology transfer with a strong focus on healthcare. We look for unique technologies that come from Czech and foreign science. We always try to find something new and unique, something that could bring great benefit to patients and also to our investors," says Jaromír Zahrádka for The podcast is in the Czech language.

sklo jaromir_mensi.jpg

Sep 28, 2022

Smart bandages not only capture pathogens, but also destroy them in no time. All they need is ordinary light.

Hospital-acquired infections are a problem that current technologies are not able to deal with effectively. However, this could change in the future; the Czech spin-off LAM-X a.s. is working on the development of a nanomaterial that not only passively prevents pathogens from entering open wounds, but can also actively destroy them ...

lamx tym.jpg

Sep 13, 2022

CasInvent Pharma raises €1.3M from KHAN-I and i&i Bio for the development of CK1 inhibitors for the treatment of cancers

CasInvent Pharma, an early-stage drug discovery company developing small-molecule compounds with anticancer properties, has raised an investment round of €1.3 million provided by KHAN-I and i&i Bio. With this funding, CasInvent will be strengthening its portfolio of CK inhibitors and progressing its lead compound to ...

Kamil Paruch with colleagues.jpg

i&i Prague Highlights

Highlights from i&i Bio

We have moved the investment part of our business to our associated venture capital firm, i&i Biotech Fund I. Here you can find the most important news from (i&i Bio).

i&i Biotech Fund will invest up to EUR 340 000 into Czech startup Sophomer s.r.o. 

Mar 15, 2023

The Czech academic startup Sophomer s.r.o. has announced an investment of up to EUR 340 000 from i&i Biotech Fund. The funding will be used for further technology development, team expansion and new laboratory space. Sophomer s.r.o. was established at the end of 2022 ...

The Advisory Committee of i&i Biotech Fund strengthened by renowned economist Daniel Münich

Jan 4, 2023

i&i Biotech Fund announces the launch of cooperation with Associate Professor Daniel Münich, who has joined the Fund's Advisory Committee. The renowned Czech economist will join the European Investment Fund's (EIF) delegate as a representative of the bio-innovation center, i&i Prague, ...

Experienced businessmen join forces with excellent science, invest EUR 2 million in the fund at the IOCB

Nov 30, 2022

Leading Czech businessmen have joined the support of the most promising scientific projects. Eight prominent entrepreneurs have contributed nearly €2 million to the i&i Biotech Fund (i&i Bio), an investment fund that specializes in finding and developing unique academic startups in the ...

i&i Bio invests more than €1 M in Enzyre to help to advance pioneering diagnostic technology platform for hemophilia patients

Nov 2, 2022

Enzyre, a company developing a breakthrough ambulant diagnostic technology for blood coagulation testing, today announced that it has successfully raised EUR 12 million Series A funding led by new investor Oost NL, with participation from i&i Biotech Fund, Demcon Investment ...

Other news

Jaromír Zahrádka: Investments help science to serve people
Our notes from a trip to “The most startup friendly country in the whole world”
i&i Prague announces its first exit, DIANA Biotechnologies is bought out by its founders
The judges at Transfera Technology Day 2021 awarded the cream of the crop
Spin-off CasInvent Pharma receives the Neuron Award for excellent Technology Transfer
i&i Bio, the newly estabilished investment fund powered by i&i Prague and EIF
i&i Prague supports the innovative PEP-Therapy in their extension of the Series-A financing,...
Licensing agreement for a novel SARS Cov-2 virus neutralization antibody test was signed
Green chemistry start-up Sulfotools closes seed round with i&i Prague
Enantis concluded a license agreement for the production of stabilised growth factor FGF2
i&i Prague supported LAM-X a.s. won the 2020 EIT Health MedTech Bootcamp final ...
CasInvent Pharma, an University Spin-Off Focused on Developing Cancer Drugs Established...
PerioTrap Pharmaceuticals Raises €3M Seed Round to Develop Selective Anti-infectives to ...
UCT Prague entered in memorandum with i&i Prague, s.r.o.
Dracen Announces the Initiation of First-in-human Study of DRP-104 in Adult Patients With ...
Elphogene received a TA CR grant for “Sample prep system and technology for cancer ..." 
bottom of page